DelveInsight's 2026 report reveals a robust pipeline with 75+ drugs under development for Duchenne muscular dystrophy (DMD), involving 70+ companies. Key therapies focus on gene and mutation-targeted approaches to slow disease progression, addressing a high unmet medical need. Recent FDA fast track designations and late-stage trials highlight promising advances, with several drugs nearing approval. This growing pipeline indicates strong future growth potential in the DMD treatment market.
Eramet has appointed Simon Henochsberg as its new Group Chief Financial Officer and member of the Executive Committee, effective May 26, 2026. Henochsberg, who previously served as Vice President of Group Strategy and co-Chief Financial Officer, brin...
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
Salazar Resources announced a new copper-gold porphyry system discovery at its 100%-owned Monja Project in southern Ecuador, featuring high-grade surface samples. This discovery comes as global copper prices hit record highs due to supply deficits, i...
